Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05773664
Other study ID # 22367
Secondary ID NCI-2023-0000722
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date August 15, 2024
Est. completion date November 29, 2024

Study information

Verified date April 2024
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial tests the safety, side effects, and best dose of dexamethasone when given with azeliragon in managing cerebral edema after surgery (post-resection) in patients with glioblastoma. Cerebral edema is a pathological increase in the water mass contained within the brain interstitial space. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Azeliragon is an oral RAGE inhibitor. Blocking the RAGE pathway at the time of surgery (peri-operatively) may decrease cerebral edema. Giving dexamethasone with azeliragon may help control post-operative cerebral edema in decreasing doses of concurrently administered dexamethasone.


Description:

PRIMARY OBJECTIVES: I. Determine the lowest dose of dexamethasone that needs to be co-administered with azeliragon for treatment of post-resection cerebral edema in patients with glioblastoma. II. Assess the safety of administering azeliragon peri-operatively to patients with glioblastoma. SECONDARY OBJECTIVES: I. Describe post-operative changes in levels of cytokines and chemokines in brain interstitium and peripheral blood in study participants. II. Quantitatively assess changes in the volume of cerebral edema post-operatively in study participants. III. Determine brain concentrations of azeliragon in resected tumor tissue from Arm 1 participants. EXPLORATORY OBJECTIVES: I. Describe post-operative changes in levels of RAGE ligands in brain interstitium, peripheral blood, and resection cavity fluid (when possible to obtain) in study participants. II. Describe changes in levels of cytokines, chemokines, and immune cell populations in resection cavity fluid (when possible to obtain). III. Describe differences in levels of cytokines, chemokines and RAGE ligands between patients in Arm 1 and Arm 2. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive azeliragon orally (PO) and dexamethasone PO or intravenously (IV) throughout the study. Patients also undergo collection of cavity fluid and blood samples, computed tomography (CT) scan, and brain magnetic resonance imaging (MRI) with or without contrast throughout the study. ARM II: Patients receive dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 21
Est. completion date November 29, 2024
Est. primary completion date November 29, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented informed consent of the participant and/or legally authorized representative - Age: >= 18 years - Karnofsky performance status of >= 60% - Histologically confirmed glioblastoma or radiographic findings consistent with a high grade glioma in patients undergoing surgery for initial diagnosis - If midline shift is present on the pre-op brain MRI, it must be less than 10 mm - The patient is planning to undergo a standard of care craniotomy, and the neurosurgeon anticipates being able to perform a gross total resection of tumor - If a patient is taking more than 3 mg twice daily (bid) of dexamethasone at the time of signing the consent form, it is anticipated by the neurosurgeon that the participant will be able to decrease their dose of dexamethasone to 3 mg bid by 6 days before the surgery - Note: If the patient is not able to decrease their dose of dexamethasone to 3 mg BID 6 days before surgery, then the patient will not be allowed to participate in the study - The patient is not planning to participate in another clinical trial during the study period - The patient has recovered from any acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy - Absolute neutrophil count (ANC) >= 1,000/mm^3 - Platelets >= 100,000/mm^3 - Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) - Aspartate aminotransferase (AST) =< 1.5 x ULN - Alanine aminotransferase (ALT) =< 1.5 x ULN - Creatinine clearance of >= 60 mL/min by the Cockcroft-Gault formula - International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN - Activated partial thromboplastin time (aPTT) =< 1.5 x ULN - Corrected QT (QTc) =< 480 ms - Note: To be performed within 28 days prior to day 1 of protocol therapy - People of childbearing potential: negative urine or serum pregnancy test - Agreement by people of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy - Childbearing potential defined as not being surgically sterilized (regardless of gender) or not being free from menses for > 1 year (people with uteri only) Exclusion Criteria: - Less than 6 weeks since taking a nitrosourea-containing chemotherapy regimen; less than 4 weeks since completing a non-nitrosourea-containing cytotoxic chemotherapy regimen (except temozolomide: only patients with an interval of less than 23 days from the last dose administered when treated with the temozolomide regimen of daily for 5 days, repeated every 28 days are excluded); less than 2 weeks from taking the last dose of a targeted agent; less than 4 weeks from the last dose of bevacizumab - Less than 3 months since focal brain radiation unless recurrent disease has been confirmed surgically or the area of recurrent tumor is outside of the radiation field - The patient is taking a medication that is a strong CYP3A4 inducers/ inhibitors within 14 days prior to day -6 of protocol therapy - The patient is unwilling to stop taking herbal medications prior to the start of study treatment - The patient is taking a hepatic enzyme-inducing anticonvulsant within 14 days prior to day -6 of protocol therapy - Clinically significant uncontrolled illness - Active infection requiring antibiotics - Human immunodeficiency virus (HIV)-positive - Undergoing treatment for another cancer - Issues with tolerating oral medication (e.g. inability to swallow pills, malabsorption issues, ongoing nausea or vomiting) - Chronic or active viral infection of the central nervous system (CNS) - Pregnant or breastfeeding - Coagulopathy or bleeding disorder - Inability to undergo a brain MRI - Inability to tolerate dexamethasone - Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures - Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azeliragon
Given PO
Procedure:
Biospecimen Collection
Undergo collection of cavity fluid and blood samples
Computed Tomography
Undergo CT scan
Drug:
Dexamethasone
Given PO or IV
Procedure:
Magnetic Resonance Imaging of the Brain with and without Contrast
Undergo MRI with or without contrast

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lack of feasibility Defined by exceeding the planned total dose of dexamethasone (per dose level) during post-operative days 1 to 8 by approximately 50%. Up to 8 days after surgery
Primary Incidence of adverse events Azeliragon related adverse events and dose limiting toxicity rate assessed per Common Terminology Criteria for Adverse Events version 5.0. Up to 30 days post-last dose of protocol therapy
Secondary Cytokines/chemokines Will assess cytokines/chemokines in brain interstitium and peripheral blood. The cytokine and chemokine levels will be measured as concentrations (pg/mL) and reported as a median with range. Up to 3 days after surgery
Secondary Volume of cerebral edema Will assess volume of cerebral edema for each post-surgery brain magnetic resonance imaging (MRI) as measured qualitatively and quantitatively by manual segmentation and computer assisted techniques. Up to 8 days after surgery
Secondary Azeliragon concentrations Will assess azeliragon concentrations in tumor samples compared to azeliragon concentrations in blood. Up to 8 days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs